You are here
Cost-Effectiveness of Screening Asymptomatic Carotid Stenosis by Atherosclerotic Cardiovascular Risk.
Tuesday,2024-09-17 14:01 America/Los_Angeles — ecterry
| Title | Cost-Effectiveness of Screening Asymptomatic Carotid Stenosis by Atherosclerotic Cardiovascular Risk. |
| Publication Type | Journal Article |
| Year of Publication | 2024 |
| Authors | Zhu, J, Jhang, J, Yu, H, Mushlin, AI, Kamel, H, Alemayehu, N, Giardina, JC, Gupta, A, Pandya, A |
| Journal | medRxiv |
| Date Published | 2024 May 16 |
| Abstract | <p><b>IMPORTANCE: </b>Extracranial internal carotid artery stenosis (50-99% arterial narrowing) is an important risk factor for ischemic stroke. Yet, the benefits and harms of targeted screening for asymptomatic carotid artery stenosis (ACAS) have not been assessed in population-based studies.</p><p><b>OBJECTIVE: </b>To estimate the cost-effectiveness of one-time, targeted ACAS screening stratified by atherosclerotic cardiovascular disease (ASCVD) risk using the American Heart Association's Pooled Cohort Equations.</p><p><b>DESIGN SETTING AND PARTICIPANTS: </b>We developed a lifetime microsimulation model of ACAS and stroke for a hypothetical cohort representative of US adults aged 50-80 years without stroke history. We used the Cardiovascular Health Study to estimate the probability and severity of ACAS based on individual characteristics (e.g., age, sex, smoking status, blood pressure, and cholesterol). Stroke risks were functions of these characteristics and ACAS severity. In the model, individuals testing positive for >70% stenosis with Duplex ultrasound and a confirmatory diagnostic test undergo revascularization, which may reduce the risk of stroke but also introduces complication risks. Diagnostic performance parameters, revascularization benefits and risks, utility weights, and costs were estimated from published sources. Cost-effectiveness was assessed from the health care sector perspective using a $100,000/quality-adjusted life year (QALY) threshold.</p><p><b>MAIN OUTCOMES AND MEASURES: </b>Estimated stroke events prevented, lifetime costs, QALYs, and incremental cost-effectiveness ratios (ICERs) associated with ACAS screening. Costs (2023 USD) and QALYs were discounted at 3% annually.</p><p><b>RESULTS: </b>We found that screening individuals with a 10-year ASCVD risk >30% was the most cost-effective strategy, with an ICER of $89,000/QALY. This strategy would make approximately 11.9% of the population eligible for screening, averting an estimated 24,084 strokes. Results were sensitive to variations in the efficacy and complication risk of revascularization. In probabilistic sensitivity analysis, screening those in lower ASCVD risk groups (0-20%) only had a 0.6% chance of being cost-effective.</p><p><b>CONCLUSION AND RELEVANCE: </b>A one-time screening may only be cost-effective for adults at a relatively high ASCVD risk. Our findings provide a framework that can be adapted as future clinical trial data continue to improve our understanding of the role of revascularization and intensive medical therapy in contemporary stroke prevention secondary to carotid disease.</p> |
| DOI | 10.1101/2023.11.28.23299146 |
| Alternate Journal | medRxiv |
| PubMed ID | 38798437 |
| PubMed Central ID | PMC11118553 |
ePub date:
24/05